CLSD vs. EYEN, FBLG, ERAS, LXRX, SLRN, BMEA, TBPH, CTNM, ESPR, and ACIU
Should you be buying Clearside Biomedical stock or one of its competitors? The main competitors of Clearside Biomedical include Eyenovia (EYEN), FibroBiologics (FBLG), Erasca (ERAS), Lexicon Pharmaceuticals (LXRX), Acelyrin (SLRN), Biomea Fusion (BMEA), Theravance Biopharma (TBPH), Contineum Therapeutics (CTNM), Esperion Therapeutics (ESPR), and AC Immune (ACIU). These companies are all part of the "pharmaceutical preparations" industry.
Eyenovia (NASDAQ:EYEN) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.
25.8% of Eyenovia shares are held by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are held by institutional investors. 7.1% of Eyenovia shares are held by insiders. Comparatively, 9.2% of Clearside Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Eyenovia has a net margin of 0.00% compared to Eyenovia's net margin of -413.73%. Eyenovia's return on equity of 0.00% beat Clearside Biomedical's return on equity.
In the previous week, Clearside Biomedical had 1 more articles in the media than Eyenovia. MarketBeat recorded 3 mentions for Clearside Biomedical and 2 mentions for Eyenovia. Clearside Biomedical's average media sentiment score of 1.58 beat Eyenovia's score of 0.63 indicating that Eyenovia is being referred to more favorably in the media.
Eyenovia has higher earnings, but lower revenue than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks.
Eyenovia has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500.
Clearside Biomedical received 186 more outperform votes than Eyenovia when rated by MarketBeat users. Likewise, 67.17% of users gave Clearside Biomedical an outperform vote while only 65.13% of users gave Eyenovia an outperform vote.
Eyenovia presently has a consensus target price of $10.00, indicating a potential upside of 1,137.62%. Clearside Biomedical has a consensus target price of $4.50, indicating a potential upside of 221.43%. Given Clearside Biomedical's higher possible upside, research analysts plainly believe Eyenovia is more favorable than Clearside Biomedical.
Summary
Clearside Biomedical beats Eyenovia on 10 of the 16 factors compared between the two stocks.
Get Clearside Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLSD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Clearside Biomedical Competitors List
Related Companies and Tools
